HALO
Halozyme Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.02 / 10
Outperform
Analyst coverage is overwhelmingly bullish with a 100% Strong Buy rating from two institutions, and fund-flow data show a good score of 7.9 with positive block and large-inflow trends. However, small-inflow dynamics are negative, indicating some retail hesitation. This combination supports the idea of institutional confidence but also highlights short-term volatility.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-08
InstitutionTD Cowen
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for HALO?
- HALO holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.02/10 (Outperform).
